Laurent G, Carlier M B, Rollman B, Van Hoof F, Tulkens P
Biochem Pharmacol. 1982 Dec 1;31(23):3861-70. doi: 10.1016/0006-2952(82)90303-3.
Gentamicin, a widely used aminoglycoside antibiotic, is concentrated in lysosomes of proximal tubular cells of the kidney, and induces therein an accumulation of myelin-like material. We show that treatment of rats with Gentamicin (10 mg/kg, 7 days) induces a loss of activity of lysosomal sphingomyelinase and phospholipase A1, associated with an increase in the amount of total lipid phosphorus in the kidney cortex. In vitro, Gentamicin is shown by gel permeation to bind to phospholipid bilayers (liposomes) under conditions which mimic the lysosomal environment (acid pH and presence of phosphatidylinositol). The reversal of this binding by an increase in the ionic strength (less than 0.04) suggests electrostatic interaction between the hydrophilic, polycationic aminoglycoside and the negatively charged phospholipids. Binding of Gentamicin impairs the hydrolysis of phosphatidylcholine present in the bilayer, by lysosomal phospholipases A1 and A2 from the liver or kidney. We also show that lysosomal sphingomyelinase is readily and irreversibly inactivated by liposomes in the absence of detergent. The lysosomal phospholipidosis induced by Gentamicin in the kidney, as in cultured cells [Aubert-Tulkens et al., Lab. Invest. 40, 481 (1979)] appears therefore to be a direct consequence of the lysosomotropic character of this drug and its ability to inhibit therein phospholipid breakdown. Amikacin, a semi-synthetic aminoglycoside, binds more loosely to phospholipid bilayers, induces less inhibition of phospholipases in vitro and is less taken up by tubular cells in vivo. Accordingly, Amikacin does not provoke significant lysosomal phospholipidosis or loss of sphingomyelinase and phospholipase A1 activities in vivo at the doses and time investigated (0-40 mg/kg, 7 days). Inasmuch as Amikacin is reported to be less toxic to the kidney, we suggest that lysosomal alterations are an early and significant step in aminoglycoside-induced nephrotoxicity.
庆大霉素是一种广泛使用的氨基糖苷类抗生素,它在肾近端小管细胞的溶酶体中蓄积,并在其中诱导髓鞘样物质的积累。我们发现,用庆大霉素(10mg/kg,7天)处理大鼠会导致溶酶体鞘磷脂酶和磷脂酶A1活性丧失,同时肾皮质中总脂质磷含量增加。在体外,通过凝胶渗透法表明,在模拟溶酶体环境(酸性pH值和存在磷脂酰肌醇)的条件下,庆大霉素可与磷脂双层(脂质体)结合。离子强度增加(小于0.04)可使这种结合逆转,这表明亲水性的聚阳离子氨基糖苷与带负电荷的磷脂之间存在静电相互作用。庆大霉素的结合会损害脂质体中磷脂酰胆碱被肝脏或肾脏的溶酶体磷脂酶A1和A2水解。我们还发现,在没有去污剂的情况下,溶酶体鞘磷脂酶很容易被脂质体不可逆地灭活。因此,庆大霉素在肾脏中诱导的溶酶体磷脂沉积症,与在培养细胞中一样[奥伯特 - 图尔肯斯等人,《实验医学杂志》40,481(1979)],似乎是这种药物的溶酶体趋向性及其抑制磷脂分解能力的直接后果。阿米卡星是一种半合成氨基糖苷类抗生素,它与磷脂双层的结合较松散,在体外对磷脂酶的抑制作用较小,并且在体内被肾小管细胞摄取较少。因此,在所研究的剂量和时间(0 - 40mg/kg,7天)下,阿米卡星在体内不会引起明显的溶酶体磷脂沉积症或鞘磷脂酶和磷脂酶A1活性丧失。鉴于据报道阿米卡星对肾脏的毒性较小,我们认为溶酶体改变是氨基糖苷类抗生素诱导肾毒性的早期且重要的步骤。